Page 17 - Practice Patterns News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Practice patterns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Practice Patterns Today - Breaking & Trending Today

Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United States , Frank Maddux , Vifor Pharma , Abbas Hussain , Derek Chalmers , Swiss Stock Exchange , Drug Administration , Swiss Exchange , International Journal Of Nephrology , Exchange Commission , Us Centers For Medicare , Vifor Pharma Group , National Registry Study , Medicaid Services , Fresenius Medical Care , Cara Therapeutics , New Drug Application , Priority Review , Chief Executive Officer , Global Chief Medical Officer , Fresenius Medical , New England Journal , Vifor Fresenius Medical Care Renal Pharma , Fresenius Medical Care North America , Pharma Group , Therapy Designation ,

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United States , Vifor Pharma , Abbas Hussain , Julien Vignot , Claire Lacagnina , Janhavi Mohite , Derek Chalmers , Frank Maddux , Nathalie Ponnier , Stern Investor Relations Inc , Swiss Stock Exchange , Drug Administration , Global Head Corporate Communications , Swiss Exchange , International Journal Of Nephrology , Exchange Commission , Us Centers For Medicare , Vifor Pharma Group , National Registry Study , Medicaid Services , Fresenius Medical Care , Cara Therapeutics , Priority Review , Chief Executive Officer , Global Chief Medical Officer , New Drug Application ,

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the ...

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Vifor Pharma , Julien Vignot , Claire Lacagnina , Janhavi Mohite , Derek Chalmers , Stefan Schulze , Nathalie Ponnier , Stern Investor Relations Inc , Swiss Stock Exchange , Global Head Corporate Communications , Swiss Exchange , International Journal Of Nephrology , Exchange Commission , Cara Therapeutics Inc , Vifor Pharma Group , European Union , European Medicines Agency , National Registry Study , Fresenius Medical Care , Fresenius Medical Care Renal Pharma , Cara Therapeutics , Marketing Authorization Application , New Drug Application , Chief Executive Officer , Investor Relations , Pharma Group ,

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Vifor Pharma , Julien Vignot , Claire Lacagnina , Janhavi Mohite , Derek Chalmers , Stefan Schulze , Nathalie Ponnier , Stern Investor Relations Inc , Swiss Stock Exchange , Global Head Corporate Communications , Swiss Exchange , International Journal Of Nephrology , Exchange Commission , Cara Therapeutics Inc , Vifor Pharma Group , European Union , European Medicines Agency , National Registry Study , Fresenius Medical Care , Vifor Fresenius Medical Care Renal Pharma , Cara Therapeutics , Marketing Authorization Application , New Drug Application , Chief Executive Officer , Investor Relations , Pharma Group ,

Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

Vifor Pharma
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™ injection in hemodialysis patients with moderate-to-severe pruritus
Monday, March 8, 2021 1:10PM IST (7:40AM GMT)

St. Gallen, Switzerland & Stamford, Conn., United States:

FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021
If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients
Regulatory News:

Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA™ is 23 ....

United States , Vifor Pharma , Julien Vignot , Claire Lacagnina , Janhavi Mohite , Derek Chalmers , Stefan Schulze , Nathalie Ponnier , Stern Investor Relations Inc , Swiss Stock Exchange , Drug Administration , Global Head Corporate Communications , Swiss Exchange , International Journal Of Nephrology , Exchange Commission , Cara Therapeutics Inc , Vifor Pharma Group , National Registry Study , Fresenius Medical Care , Prescription Drug User Fee Act , Cara Therapeutics , Priority Review , New Drug Application , New England Journal , Chief Executive Officer , Chronic Kidney Disease Associated Pruritus ,